Novel Oral AntiCoagulants (NOAC) Market - Global Professional Analysis and Forecast to 2026

  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • The worldwide Novel Oral AntiCoagulants (NOAC) market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 6.4% during the forecast period.

    This report presents the market size and development trends by detailing the Novel Oral AntiCoagulants (NOAC) market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Novel Oral AntiCoagulants (NOAC) market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Novel Oral AntiCoagulants (NOAC) industry and will help you to build a panoramic view of the industrial development.

    Novel Oral AntiCoagulants (NOAC) Market, By Type:

    • Direct Thrombin Inhibitors

    • Direct Factor Xa Inhibitors

    Novel Oral AntiCoagulants (NOAC) Market, By Application:

    • Deep Vein Thrombosis (DVT)

    • Pulmonary Embolism

    • Acute Coronary Syndrome

    • Hemodialysis

    • Others

    Some of the leading players are as follows:

    • CSL Behring

    • Daiichi Sankyo

    • Cosmo Pharmaceuticals

    • Marathon Pharmaceuticals

    • Boehringer Ingelheim

    • Bristol-Myers Squibb

    • Ockham Biotech

    • Sanofi

    • Bayer

    • Johnson & Johnson

    • GSK

    • Armatheon

    • Cellceutix

    • AstraZeneca

    • Aspen

    • Eisai

    • Perosphere

    Geographically, Major regions are analyzed in details are as follows:

    • North America

    • Europe

    • Asia Pacific

    • Latin America

    • Middle East & Africa

  • Table of Contents

    1 Methodology and Scope

    • 1.1 Market Segmentation & Scope

      • 1.1.1 Technology Type

      • 1.1.2 Product

      • 1.1.3 Application

      • 1.1.4 Regional scope

      • 1.1.5 Estimates and forecast timeline

    • 1.2 Research Methodology

    • 1.3 Information Procurement

      • 1.3.1 Purchased database

      • 1.3.2 Internal database

      • 1.3.3 Secondary sources

      • 1.3.4 Primary research

      • 1.3.5 Details of primary research

    • 1.4 Information or Data Analysis

      • 1.4.1 Data analysis models

    • 1.5 Market Formulation & Validation

    • 1.6 Model Details

      • 1.6.1 Commodity flow analysis

      • 1.6.2 Volume price analysis

    • 1.7 List of Secondary Sources

    • 1.8 List of Abbreviations

    2 Executive Summary

    • 2.1 Market Outlook

    • 2.2 Segment Outlook

    3 Market Variables, Trends, & Scope

    • 3.1 Market Lineage Outlook

    • 3.1.1 Parent market outlook

      • 3.1.2 Ancillary market outlook

    • 3.2 Market Segmentation

      • 3.2.1 Analysis

    • 3.3 Market Dynamics

      • 3.3.1 Market driver analysis

      • 3.3.2 Market restraint analysis

      • 3.3.3 Industry opportunities

    • 3.4 Penetration & Growth Prospect Mapping

      • 3.4.1 Penetration & growth prospect mapping analysis

    • 3.5 Business Environment Analysis Tools

      • 3.5.1 Porter's five forces analysis

      • 3.5.2 PESTLE analysis

      • 3.5.3 Major deals & strategic alliances analysis

    4 Novel Oral AntiCoagulants (NOAC) Market: Technology Type Analysis

    • 4.1 Novel Oral AntiCoagulants (NOAC) Technology Type Market Share Analysis, 2018 & 2026

    • 4.2 Novel Oral AntiCoagulants (NOAC) Technology Type Market: Segment Dashboard

    • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

      • 4.3.1 Direct Thrombin Inhibitors

      • 4.3.2 Direct Factor Xa Inhibitors

    5 Novel Oral AntiCoagulants (NOAC) Market: Product Analysis

    • 5.1 Novel Oral AntiCoagulants (NOAC) Product Market Share Analysis, 2018 & 2026

    • 5.2 Novel Oral AntiCoagulants (NOAC) Product Market: Segment Dashboard

    • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

    6 Novel Oral AntiCoagulants (NOAC) Market: Application Analysis

    • 6.1 Novel Oral AntiCoagulants (NOAC) Application Market Share Analysis, 2018 & 2026

    • 6.2 Novel Oral AntiCoagulants (NOAC) Application Market: Segment Dashboard

    • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

      • 6.3.1 Deep Vein Thrombosis (DVT)

      • 6.3.2 Pulmonary Embolism

      • 6.3.3 Acute Coronary Syndrome

      • 6.3.4 Hemodialysis

      • 6.3.5 Others

    7 Novel Oral AntiCoagulants (NOAC) Market: Regional Analysis

    • 7.1 Novel Oral AntiCoagulants (NOAC) Regional Market Share Analysis, 2018 & 2026

    • 7.2 Novel Oral AntiCoagulants (NOAC) Regional Market: Segment Dashboard

    • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

    • 7.4 List of Players at Regional Level

      • 7.4.1 North America

      • 7.4.2 Europe

      • 7.4.3 Asia Pacific

    • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

      • 7.5.1 North America

      • 7.5.2 Europe

      • 7.5.3 Asia Pacific

      • 7.5.4 Latin America

      • 7.5.5 MEA

    • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

      • 7.6.1 North America

      • 7.6.2 Europe

      • 7.6.3 Asia Pacific

      • 7.6.4 Latin America

      • 7.6.5 Middle East & Africa

    8 Competitive Analysis

    • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

    • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

    • 8.3 Vendor Landscape

      • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

    9 Company Profiles

    • 9.1 CSL Behring

      • 9.1.1 CSL Behring Company overview

      • 9.1.2 Financial performance

      • 9.1.3 Product benchmarking

      • 9.1.4 Strategic initiatives

      • 9.1.5 SWOT analysis

    • 9.2 Daiichi Sankyo

      • 9.2.1 Daiichi Sankyo Company overview

      • 9.2.2 Financial performance

      • 9.2.3 Product benchmarking

      • 9.2.4 Strategic initiatives

      • 9.2.5 SWOT analysis

    • 9.3 Cosmo Pharmaceuticals

      • 9.3.1 Cosmo Pharmaceuticals Company overview

      • 9.3.2 Financial performance

      • 9.3.3 Product benchmarking

      • 9.3.4 Strategic initiatives

      • 9.3.5 SWOT analysis

    • 9.4 Marathon Pharmaceuticals

      • 9.4.1 Marathon Pharmaceuticals Company overview

      • 9.4.2 Financial performance

      • 9.4.3 Product benchmarking

      • 9.4.4 Strategic initiatives

      • 9.4.5 SWOT analysis

    • 9.5 Boehringer Ingelheim

      • 9.5.1 Boehringer Ingelheim Company overview

      • 9.5.2 Financial performance

      • 9.5.3 Product benchmarking

      • 9.5.4 Strategic initiatives

      • 9.5.5 SWOT analysis

    • 9.6 Bristol-Myers Squibb

      • 9.6.1 Bristol-Myers Squibb Company overview

      • 9.6.2 Financial performance

      • 9.6.3 Product benchmarking

      • 9.6.4 Strategic initiatives

      • 9.6.5 SWOT analysis

    • 9.7 Ockham Biotech

      • 9.7.1 Ockham Biotech Company overview

      • 9.7.2 Financial performance

      • 9.7.3 Product benchmarking

      • 9.7.4 Strategic initiatives

      • 9.7.5 SWOT analysis

    • 9.8 Sanofi

      • 9.8.1 Sanofi Company overview

      • 9.8.2 Financial performance

      • 9.8.3 Product benchmarking

      • 9.8.4 Strategic initiatives

      • 9.8.5 SWOT analysis

    • 9.9 Bayer

      • 9.9.1 Bayer Company overview

      • 9.9.2 Financial performance

      • 9.9.3 Product benchmarking

      • 9.9.4 Strategic initiatives

      • 9.9.5 SWOT analysis

    • 9.10 Johnson & Johnson

      • 9.10.1 Johnson & Johnson Company overview

      • 9.10.2 Financial performance

      • 9.10.3 Product benchmarking

      • 9.10.4 Strategic initiatives

      • 9.10.5 SWOT analysis

    • 9.11 GSK

      • 9.11.1 GSK Company overview

      • 9.11.2 Financial performance

      • 9.11.3 Product benchmarking

      • 9.11.4 Strategic initiatives

      • 9.11.5 SWOT analysis

    • 9.12 Armatheon

      • 9.12.1 Armatheon Company overview

      • 9.12.2 Financial performance

      • 9.12.3 Product benchmarking

      • 9.12.4 Strategic initiatives

      • 9.12.5 SWOT analysis

    • 9.13 Cellceutix

      • 9.13.1 Cellceutix Company overview

      • 9.13.2 Financial performance

      • 9.13.3 Product benchmarking

      • 9.13.4 Strategic initiatives

      • 9.13.5 SWOT analysis

    • 9.14 AstraZeneca

      • 9.14.1 AstraZeneca Company overview

      • 9.14.2 Financial performance

      • 9.14.3 Product benchmarking

      • 9.14.4 Strategic initiatives

      • 9.14.5 SWOT analysis

    • 9.15 Aspen

      • 9.15.1 Aspen Company overview

      • 9.15.2 Financial performance

      • 9.15.3 Product benchmarking

      • 9.15.4 Strategic initiatives

      • 9.15.5 SWOT analysis

    • 9.16 Eisai

      • 9.16.1 Eisai Company overview

      • 9.16.2 Financial performance

      • 9.16.3 Product benchmarking

      • 9.16.4 Strategic initiatives

      • 9.16.5 SWOT analysis

    • 9.17 Perosphere

      • 9.17.1 Perosphere Company overview

      • 9.17.2 Financial performance

      • 9.17.3 Product benchmarking

      • 9.17.4 Strategic initiatives

      • 9.17.5 SWOT analysis

     

    The List of Tables and Figures (Totals 102 Figures and 165 Tables)

    • Figure Direct Thrombin Inhibitors Novel Oral AntiCoagulants (NOAC) market, 2015 - 2026 (USD Million)

    • Figure Direct Factor Xa Inhibitors Novel Oral AntiCoagulants (NOAC) market, 2015 - 2026 (USD Million)

    • Figure Deep Vein Thrombosis (DVT) market, 2015 - 2026 (USD Million)

    • Figure Pulmonary Embolism market, 2015 - 2026 (USD Million)

    • Figure Acute Coronary Syndrome market, 2015 - 2026 (USD Million)

    • Figure Hemodialysis market, 2015 - 2026 (USD Million)

    • Figure Others market, 2015 - 2026 (USD Million)

    • Table List of players in North America

    • Table List of players in Europe

    • Table List of players in Asia Pacific

    • Table SWOT analysis

    • Table North America Novel Oral AntiCoagulants (NOAC) market, by country, 2015 - 2026 (USD Million)

    • Table North America Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table North America Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table North America Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.S. Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table U.S. Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table U.S. Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Canada Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table Canada Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table Canada Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Europe Novel Oral AntiCoagulants (NOAC) market, by country, 2015 - 2026 (USD Million)

    • Table Europe Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table Europe Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table Europe Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.K. Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table U.K. Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table U.K. Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Germany Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table Germany Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table Germany Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table France Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table France Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table France Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Italy Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table Italy Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table Italy Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Spain Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table Spain Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table Spain Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Asia Pacific Novel Oral AntiCoagulants (NOAC) market, by country, 2015 - 2026 (USD Million)

    • Table Asia Pacific Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table Asia Pacific Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table Asia Pacific Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table China Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table China Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table China Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Japan Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table Japan Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table Japan Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table India Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table India Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table India Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Latin America Novel Oral AntiCoagulants (NOAC) market, by country, 2015 - 2026 (USD Million)

    • Table Latin America Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table Latin America Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table Latin America Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Brazil Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table Brazil Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table Brazil Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Mexico Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table Mexico Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table Mexico Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Argentina Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table Argentina Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table Argentina Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table MEA Novel Oral AntiCoagulants (NOAC) market, by country, 2015 - 2026 (USD Million)

    • Table MEA Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table MEA Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table MEA Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table South Africa Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table South Africa Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table South Africa Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Nigeria Novel Oral AntiCoagulants (NOAC) market, by type, 2015 - 2026 (USD Million)

    • Table Nigeria Novel Oral AntiCoagulants (NOAC) market, by product, 2015 - 2026 (USD Million)

    • Table Nigeria Novel Oral AntiCoagulants (NOAC) market, by application, 2015 - 2026 (USD Million)

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Company market position analysis

    • Table Company Profiles

    • Table CSL Behring Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Daiichi Sankyo Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Cosmo Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Marathon Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Boehringer Ingelheim Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Ockham Biotech Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Sanofi Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Bayer Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Johnson & Johnson Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table GSK Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Armatheon Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Cellceutix Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Aspen Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Eisai Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Perosphere Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.